A securities class-action lawsuit is underway against Sarepta Therapeutics (NASDAQ: SRPT) , triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit ...

As investors rotate away from the Magnificent 7, buy-rated small-caps like Chemours, Hillenbrand, and Arrowhead ...